pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 39 Non-oncology: 25
Oncology: 14
Under Consideration for Negotiation 11 Non-oncology: 6
Oncology: 5
Completed Negotiations 803 With Letter of Intent: 695
Without agreement: 108
Negotiations That Were Not Pursued 109

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus
Imdelltra Amgen Canada Inc. For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy
Fabhalta Novartis Pharmaceuticals Canada Inc. Paroxysmal nocturnal hemoglobinuria (PNH)
Blincyto Amgen Canada Inc. For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.
Olumiant Eli Lilly Canada Inc. Alopecia areata, severe

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy
Livmarli Mirum Pharmaceuticals Inc. Alagille syndrome
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di
Padcev Pfizer Canada ULC In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Tibsovo Servier Canada Inc. In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy
Imcivree Rhythm Pharmaceuticals, Inc. Bardet-Biedl syndrome
Keytruda Merck Canada Inc. In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Niopeg Nora Pharma Inc. To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Jardiance Boehringer Ingelheim (Canada) Ltd. Adjunct to standard of care therapy for the treatment of chronic heart failure in adults

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ryaltris Bausch Health, Canada Inc. Seasonal allergic rhinitis